1. Home
  2. SOPH vs ALLO Comparison

SOPH vs ALLO Comparison

Compare SOPH & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SOPH
  • ALLO
  • Stock Information
  • Founded
  • SOPH 2011
  • ALLO 2017
  • Country
  • SOPH Switzerland
  • ALLO United States
  • Employees
  • SOPH N/A
  • ALLO N/A
  • Industry
  • SOPH Biotechnology: Biological Products (No Diagnostic Substances)
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SOPH Health Care
  • ALLO Health Care
  • Exchange
  • SOPH Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • SOPH 231.8M
  • ALLO 231.9M
  • IPO Year
  • SOPH 2021
  • ALLO 2018
  • Fundamental
  • Price
  • SOPH $3.33
  • ALLO $1.14
  • Analyst Decision
  • SOPH
  • ALLO Strong Buy
  • Analyst Count
  • SOPH 0
  • ALLO 10
  • Target Price
  • SOPH N/A
  • ALLO $8.88
  • AVG Volume (30 Days)
  • SOPH 46.6K
  • ALLO 3.8M
  • Earning Date
  • SOPH 11-04-2025
  • ALLO 11-06-2025
  • Dividend Yield
  • SOPH N/A
  • ALLO N/A
  • EPS Growth
  • SOPH N/A
  • ALLO N/A
  • EPS
  • SOPH N/A
  • ALLO N/A
  • Revenue
  • SOPH $69,688,000.00
  • ALLO N/A
  • Revenue This Year
  • SOPH $16.60
  • ALLO N/A
  • Revenue Next Year
  • SOPH $18.77
  • ALLO $100.00
  • P/E Ratio
  • SOPH N/A
  • ALLO N/A
  • Revenue Growth
  • SOPH 7.32
  • ALLO N/A
  • 52 Week Low
  • SOPH $2.58
  • ALLO $0.86
  • 52 Week High
  • SOPH $4.92
  • ALLO $3.78
  • Technical
  • Relative Strength Index (RSI)
  • SOPH 48.80
  • ALLO 48.86
  • Support Level
  • SOPH $3.22
  • ALLO $1.06
  • Resistance Level
  • SOPH $3.49
  • ALLO $1.18
  • Average True Range (ATR)
  • SOPH 0.21
  • ALLO 0.08
  • MACD
  • SOPH -0.01
  • ALLO 0.01
  • Stochastic Oscillator
  • SOPH 22.96
  • ALLO 45.83

About SOPH SOPHiA GENETICS SA

Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: